Apimeds Pharmaceuticals US (APUS) Other Non-Current Assets (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Other Non-Current Assets came in at $75485.0 in Q4 2025, down 41.82% on a QoQ basis from $129740.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Other Non-Current Assets (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 1 years of Other Non-Current Assets data on file, last reported at $75485.0 in Q4 2025.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $75485.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75485.0 (changed N/A YoY) and the FY2025 annual result came in at $75485.0, changed N/A from the prior year.
- Other Non-Current Assets declined to $75485.0 in Q4 2025, from $129740.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $183995.0 in Q2 2025 to a low of $75485.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 7.68 Mn | 7.68 Mn | - | 33.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75,485.00 |
| Sep 30, 2025 | 129,740.00 |
| Jun 30, 2025 | 183,995.00 |